Cite
HARVARD Citation
Negrier, S. et al. (2020). Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European journal of cancer. pp. 107-116. [Online].